BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33305819)

  • 21. Pancreatic Neuroendocrine Tumors.
    Salaria SN; Shi C
    Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification.
    Ishida H; Lam AK
    Crit Rev Oncol Hematol; 2022 Apr; 172():103648. PubMed ID: 35248713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
    Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
    World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accuracy of grading pancreatic neuroendocrine neoplasms with Ki-67 index in fine-needle aspiration cellblock material.
    Grosse C; Noack P; Silye R
    Cytopathology; 2019 Mar; 30(2):187-193. PubMed ID: 30303569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Eighth Edition of the American Joint Committee on Cancer Distant Metastases Stage Classification for Metastatic Pancreatic Neuroendocrine Tumors Might Be Feasible for Metastatic Pancreatic Ductal Adenocarcinomas.
    Wen J; Chen J; Liu D; Xu X; Fan M; Zhang Z
    Neuroendocrinology; 2020; 110(5):364-376. PubMed ID: 31357196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
    Farrell JM; Pang JC; Kim GE; Tabatabai ZL
    Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes.
    Felder S; Jann H; Arsenic R; Denecke T; Prasad V; Knappe-Drzikova B; Maasberg S; Wiedenmann B; Pavel M; Pascher A; Pape UF
    Endocr Relat Cancer; 2019 Sep; 26(9):751-763. PubMed ID: 31272081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
    Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
    Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification.
    Xue Y; Reid MD; Pehlivanoglu B; Obeng RC; Jiang H; Memis B; Lui SK; Sarmiento J; Kooby D; Maithel SK; El-Rayes B; Basturk O; Adsay V
    Endocr Pathol; 2020 Sep; 31(3):239-253. PubMed ID: 32488621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pancreatic neuroendocrine tumors].
    Burgos L; Burgos ME
    Rev Med Chil; 2004 May; 132(5):627-34. PubMed ID: 15279151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The current management of pancreatic neuroendocrine tumors.
    Ellison TA; Edil BH
    Adv Surg; 2012; 46():283-96. PubMed ID: 22873046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.
    Hofland J; Falconi M; Christ E; Castaño JP; Faggiano A; Lamarca A; Perren A; Petrucci S; Prasad V; Ruszniewski P; Thirlwell C; Vullierme MP; Welin S; Bartsch DK
    J Neuroendocrinol; 2023 Aug; 35(8):e13318. PubMed ID: 37578384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances.
    Guilmette JM; Nosé V
    Adv Anat Pathol; 2019 Jan; 26(1):13-30. PubMed ID: 29912000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia.
    Inzani F; Petrone G; Rindi G
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):463-470. PubMed ID: 30098710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural history and clinical outcomes of pancreatic neuroendocrine neoplasms based on the WHO 2017 classification; a single-center experience of 30 years.
    Fujimori N; Miki M; Lee L; Matsumoto K; Takamatsu Y; Takaoka T; Teramatsu K; Suehiro Y; Murakami M; Igarashi H; Oono T; Ohtsuka T; Nakamura M; Koga Y; Oda Y; Ito T; Ogawa Y
    Pancreatology; 2020 Jun; 20(4):709-715. PubMed ID: 32360001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.
    Kim JY; Brosnan-Cashman JA; Kim J; An S; Lee KB; Kim H; Park DY; Jang KT; Oh YH; Hruban RH; Heaphy CM; Hong SM
    Pathology; 2020 Apr; 52(3):336-347. PubMed ID: 32111396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.